articleThe Lancet OncologyMay 13, 2022GREEN OA

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

BCByoung Chul ChoDRDelvys Rodríguez‐AbreuMHMaen HusseinMCManuel CoboAPA. Patel

Yonsei University · Hospital Universitario Insular de Gran Canaria · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

415
total citations
FWCI
39.42
Percentile
100%
References
15
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Atezolizumab
  • Medicine
  • Internal medicine
  • Placebo
  • Oncology
  • Population
  • TIGIT
  • Lung cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding